---
title: "Rexulti (brexpiprazole) in major depressive disorder: Dosing and administration questions"
description: "Dosing and administration questions on Rexulti (brexpiprazole) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Treatment combinations and Dosing. Questions: Which antidepressants was Rexulti studied with in depression trials? What is the Rexulti dose for depression? What is the maximum dose of Rexulti for depression? 3 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole) in major depressive disorder: Dosing and administration questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)

Dosing and administration questions that apply to every indication of Rexulti are on [Rexulti (brexpiprazole), all indications: Dosing and administration](https://www.evicenter.com/medical-information/rexulti/dosing-and-administration).

## Treatment combinations

<a id="rexulti-antidepressants-studied"></a>

### Which antidepressants was Rexulti studied with in depression trials?

> “The efficacy of REXULTI in the adjunctive treatment of major depressive disorder (MDD) was evaluated in two 
> 6-week double-blind, placebo-controlled, fixed-dose studies of adult patients meeting DSM-IV-TR criteria for 
> MDD, with or without symptoms of anxiety, who had an inadequate response to prior antidepressant therapy 
> (1 to 3 courses) in the current episode and who had also demonstrated an inadequate response throughout the 
> 8 weeks of prospective antidepressant treatment (with escitalopram, fluoxetine, paroxetine controlled-release, 
> sertraline, duloxetine delayed release, or venlafaxine extended release). Inadequate response during the 
> prospective antidepressant treatment phase was defined as having persistent symptoms without substantial 
> improvement throughout the course of treatment.”

Source: [REXULTI: Prescribing information, page 29, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=29)

> “<sup>a</sup>The antidepressants studied included SSRIs and SNRIs.”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Safety, captured 2026-11-13](https://www.rexultihcp.com/mdd/safety#:~:text=antidepressants%20studied%20included%20SSRIs%20and%20SNRIs.)

## Dosing

<a id="rexulti-dosing"></a>

### What is the Rexulti dose for depression?

> “The recommended starting REXULTI dosage for the adjunctive treatment of MDD in adults is 0.5 mg or 1 mg 
> orally once daily. Titrate to 1 mg once daily, then titrate to the target dosage of 2 mg once daily (based on the 
> patient’s clinical response and tolerability, increase the dosage at weekly intervals). The maximum 
> recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate 
> dosage for treatment.”

Source: [REXULTI: Prescribing information, page 3, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=3)

> “REXULTI—recommended target dose: 2 mg/day”

Source: [REXULTI: BROCHURE, page 1, captured 2026-11-13](https://www.rexultihcp.com/mdd/content/dam/rexulti/hcp/websites/com/live-assets/pdfs/mdd-dosing-guide.pdf#page=1)

> “Dose increases should occur at weekly intervals based on the patient’s clinical response and tolerability, and should be periodically reassessed to determine the continued need and appropriate dose for treatment”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Dosing, captured 2026-11-13](https://www.rexultihcp.com/mdd/dosing#:~:text=Dose%20increases%20should%20occur%20at,and%20appropriate%20dose%20for%20treatment)

<a id="rexulti-max-dose"></a>

### What is the maximum dose of Rexulti for depression?

> “The maximum 
> recommended daily dosage is 3 mg.”

Source: [REXULTI: Prescribing information, page 3, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=3)

Note: From section 2.2 of the Prescribing Information, Recommended Dosage for Adjunctive Treatment of Major Depressive Disorder (Adults).

## Related pages
- [Medical information: Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/drug-interactions)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/access-and-coverage)
